Development of extramedullary myeloma in the era of novel agents: no evidence of increased risk with lenalidomide-bortezomib combinations.
Varga C, Xie W, Laubach J, Ghobrial IM, O'Donnell EK, Weinstock M, Paba-Prada C, Warren D, Maglio ME, Schlossman R, Munshi NC, Raje N, Weller E, Anderson KC, Mitsiades CS, Richardson PG.
Varga C, et al. Among authors: richardson pg.
Br J Haematol. 2015 Jun;169(6):843-50. doi: 10.1111/bjh.13382.
Br J Haematol. 2015.
PMID: 26032514
Free article.